Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis

Hepatology

Volumn 48, Issue 1, 2008, Pages 109-118

  Uno, Masafumi ^a   Kurita, Seiichiro ^a   Misu, Hirofumi ^a   Ando, Hitoshi ^a   Ota, Tsuguhito ^a   Matsuzawa Nagata, Naoto ^a   Kita, Yuki ^a   Nabemoto, Satoko ^a   Akahori, Hiroshi ^a   Zen, Yoh ^a   Nakanuma, Yasuni ^a   Kaneko, Shuichi ^a   Takamura, Toshinari ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE; CHOLINE; GLUCOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; METHIONINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLASMINOGEN ACTIVATOR; PROCOLLAGEN; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DOWN REGULATION; DRUG EFFECT; ENZYME SYNTHESIS; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEPATITIS; INSULIN RESISTANCE; KUPFFER CELL; LIVER FIBROSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STELLATE CELL; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTHRANILIC ACIDS; CARNITINE O-PALMITOYLTRANSFERASE; CELL LINE; CHOLINE DEFICIENCY; DIET; FATTY ACIDS; FATTY LIVER; INTERLEUKIN-6; KUPFFER CELLS; LIPOPOLYSACCHARIDES; LIVER; LIVER CIRRHOSIS; MACROPHAGES; MALE; METHIONINE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PPAR ALPHA; RATS; RATS, INBRED OLETF; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 47149097985     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22338     Document Type: Article

References (39)

1. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001;121:710-723.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
3. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. HEPATOLOGY 2003;37:917-923.
4. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-1850.
5. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513-1517.
6. Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, Uno M, et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007;132:282-293.
7. Ota T, Takamura T, Kaneko S. Pioglitazone in nonalcoholic steatohepatitis. N Engl J Med 2007;356:1068; author reply 1068-1069.
8. Suzawa H, Kikuchi S, Ichikawa K, Koda A. Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages. Jpn J Pharmacol 1992;60:85-90.
9. Bonnet F, Cao Z, Cooper ME, Cox AJ, Kelly DJ, Gilbert RE. Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes. Diabetes Metab 2003;29:386-392.
10. Ikeda H, Inao M, Fujiwara K. Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells. Biochem Biophys Res Commun 1996;227:322-327.
11. Miyazawa K, Kikuchi S, Fukuyama J, Hamano S, Ujiie A. Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis 1995;118:213-221.
12. Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int 2006;26:8-22.
13. Chapman HA. Disorders of lung matrix remodeling. J Clin Invest 2004; 113:148-157.
14. Casini A, Pinzani M, Milani S, Grappone C, Galli G, Jezequel AM, et al. Regulation of extracellular matrix synthesis by transforming growth factor beta 1 in human fat-storing cells. Gastroenterology 1993;105:245-253.
15. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 1999;96:12719-12724.
16. Arias M, Sauer-Lehnen S, Treptau J, Janoschek N, Theuerkauf I, Buettner R, et al. Adenoviral expression of a transforming growth factor-beta1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats. BMC Gastroenterol 2003;3:29.
17. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci U S A 1999;96:2345-2349.
18. Nakamura T, Sakata R, Ueno T, Sata M, Ueno H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. HEPATOLOGY 2000;32:247-255.
19. Williams EJ, Gaca MD, Brigstock DR, Arthur MJ, Benyon RC. Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J Hepatol 2000;32:754-761.
20. Shigeki S, Murakami T, Yata N, Ikuta Y. Treatment of keloid and hypertrophic scars by iontophoretic transdermal delivery of tranilast. Scand J Plast Reconstr Surg Hand Surg 1997;31:151-158.
21. Yamada H, Tajima S, Nishikawa T, Murad S, Pinnell SR. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. J Biochem (Tokyo) 1994;116:892-897.
22. Akahori H, Ota T, Torita M, Ando H, Kaneko S, Takamura T. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression. J Pharmacol Exp Ther 2005;314:514-521.
23. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992;41:1422-1428.
24. Mathews CE, Leiter EH. Rodent models for the study of diabetes. In: Joslin's diabetes mellitus, 14th ed. Boston: Lippincott Williams & Wilkins; 2005:291-328.
25. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
26. Takamura T, Sakurai M, Ota T, Ando H, Honda M, Kaneko S. Genes for systemic vascular complications are differentially expressed in the livers of type 2 diabetic patients. Diabetologia 2004;47:638-647.
27. Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. HEPATOLOGY 2007;46:1392-1403.
28. Saiura A, Sata M, Hirata Y, Nagai R, Makuuchi M. Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation. Eur J Pharmacol 2001;433:163-168.
29. Izawa A, Suzuki J, Takahashi W, Amano J, Isobe M. Tranilast inhibits cardiac allograft vasculopathy in association with p21 (Waf1/Cip1) expression on neointimal cells in murine cardiac transplantation model. Arterioserer Thromb Vasc Biol 2001;21:1172-1178.
30. Su GL. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am J Physiol Gastrointest Liver Physiol 2002;283:G256-G265.
31. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006;10:76-99.
32. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002;7:d793-d807.
33. Bergheim I, Guo L, Davis MA, Lambert JC, Beier JI, Duveau I, et al. Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastroenterology 2006;130:2099-2112.
34. Capper EA, Roshak AK, Bolognese BJ, Podolin PL, Smith T, Dewitt DL, et al. Modulation of human monocyte activities by tranilast, SB 252218, a compound demonstrating efficacy in restenosis. J Pharmacol Exp Ther 2000;295:1061-1069.
35. Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol 2006;12:7413-7420.
36. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307.
37. Sekiguchi K, Tian Q, Ishiyama M, Burchfield J, Gao F, Mann DL, et al. Inhibition of PPAR-alpha activity in mice with cardiac-restricted expression of tumor necrosis factor: potential role of TGF-beta/Smad3. Am J Physiol Heart Circ Physiol 2007;292:H1443-H1451.
38. Lowell BB, Spiegelman BM. Towards a molecular understanding of adaptive thermogenesis. Nature 2000;404:652-660.
39. Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, Zhang CY, et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 2004;119:121-135.